Stenting, CABG Compared in Multivessel Disease

ORLANDO, FLA. — Stenting may have finally edged past coronary bypass surgery for treating multivessel coronary disease, according to the results from an uncontrolled series of 607 patients who underwent revascularization using drug-eluting stents.

One year after patients underwent multivessel revascularization with sirolimus-eluting (Cypher) coronary stents, their rate of major adverse events was better than the rate in a similar series of patients who underwent coronary bypass graft (CABG) surgery in the late 1990s, Patrick Serruys, M.D., said at the annual meeting of the American College of Cardiology.

“This study is a breakthrough,” commented Valentin Fuster, M.D., director of the cardiovascular institute at Mount Sinai Medical Center in New York. “Even though this was not a prospective, randomized, controlled study, I'm convinced that for patients with multivessel disease, drug-eluting stents may have more of an impact today on the rate of death and myocardial infarction than coronary artery bypass grafting.”

The biggest question remaining is whether surgery or drug-eluting-stent placement is the best treatment for such patients with diabetes. In the new study, 26% of enrolled patients had diabetes, so the applicability of the results to patients with diabetes remains unclear.

In this multicenter series, 54% of patients had triple-vessel disease, and 46% had two-vessel disease. All patients were treated with percutaneous coronary intervention using sirolimus-eluting coronary stents. The Arterial Revascularization Therapies Study Part II (ARTS II) was designed to test whether multivessel stenting was not inferior to CABG.

The study's primary end point was the combined rate of death, MI, stroke or transient ischemic attack, and need for revascularization 1 year after treatment. This combined rate was 10.4%, reported Dr. Serruys, chief of interventional cardiology at the thorax center of Erasmus University in Rotterdam, the Netherlands.

This rate was compared with the 11.7% rate in a very similar series of 605 patients who underwent CABG during the late 1990s in ARTS I, said Dr. Serruys.

In ARTS II, the incidence of death was 1.0%, the rate of cerebrovascular events was 0.8%, the rate of MI was 1.2%, and the rate of clinically necessary revascularization procedures was 7.4%. (See box.)

In the historic series of CABG patients, the 1-year rate of death was 2.7%, the rate of cerebrovascular events was 1.8%, the rate of MI was 3.5%, and the rate of clinically necessary revascularization was 3.7%.

Comparison of the combined adverse events showed that stenting was not inferior to CABG. The results further showed that stenting was statistically superior to bypass surgery after 1 year of follow-up, said Dr. Serruys.

After adjustment for baseline differences in the patients enrolled in both studies, the combined rate of major adverse events was 8.1% in the patients who underwent stenting and 13.1% among the patients who had bypass surgery.

The superiority of stenting with sirolimus-eluting stents in ARTS II contrasted with the results of the bare-metal-stent arm of ARTS I. In that series of 600 patients, done concurrently with the coronary bypass arm, the combined rate of major adverse events was 26.5% after 1 year, primarily because the rate of clinically necessary revascularization was 17.0%.

The difference in revascularization rates between ARTS I, with bare-metal stents, and ARTS II, with drug-eluting stents, “shows the difference that drug-eluting stents make,” commented Fayez Shamoon, M.D., a cardiologist at St. Michael's Medical Center in Newark, N.J. Based on the new results, “most interventional cardiologists would be willing to treat triple-vessel disease with a drug-eluting stent,” except in patients with diabetes, left main disease, or a left ventricular ejection fraction of 35% or less, he told this newspaper.

ORLANDO, FLA. — Stenting may have finally edged past coronary bypass surgery for treating multivessel coronary disease, according to the results from an uncontrolled series of 607 patients who underwent revascularization using drug-eluting stents.

One year after patients underwent multivessel revascularization with sirolimus-eluting (Cypher) coronary stents, their rate of major adverse events was better than the rate in a similar series of patients who underwent coronary bypass graft (CABG) surgery in the late 1990s, Patrick Serruys, M.D., said at the annual meeting of the American College of Cardiology.

“This study is a breakthrough,” commented Valentin Fuster, M.D., director of the cardiovascular institute at Mount Sinai Medical Center in New York. “Even though this was not a prospective, randomized, controlled study, I'm convinced that for patients with multivessel disease, drug-eluting stents may have more of an impact today on the rate of death and myocardial infarction than coronary artery bypass grafting.”

The biggest question remaining is whether surgery or drug-eluting-stent placement is the best treatment for such patients with diabetes. In the new study, 26% of enrolled patients had diabetes, so the applicability of the results to patients with diabetes remains unclear.

In this multicenter series, 54% of patients had triple-vessel disease, and 46% had two-vessel disease. All patients were treated with percutaneous coronary intervention using sirolimus-eluting coronary stents. The Arterial Revascularization Therapies Study Part II (ARTS II) was designed to test whether multivessel stenting was not inferior to CABG.

The study's primary end point was the combined rate of death, MI, stroke or transient ischemic attack, and need for revascularization 1 year after treatment. This combined rate was 10.4%, reported Dr. Serruys, chief of interventional cardiology at the thorax center of Erasmus University in Rotterdam, the Netherlands.

This rate was compared with the 11.7% rate in a very similar series of 605 patients who underwent CABG during the late 1990s in ARTS I, said Dr. Serruys.

In ARTS II, the incidence of death was 1.0%, the rate of cerebrovascular events was 0.8%, the rate of MI was 1.2%, and the rate of clinically necessary revascularization procedures was 7.4%. (See box.)

In the historic series of CABG patients, the 1-year rate of death was 2.7%, the rate of cerebrovascular events was 1.8%, the rate of MI was 3.5%, and the rate of clinically necessary revascularization was 3.7%.

Comparison of the combined adverse events showed that stenting was not inferior to CABG. The results further showed that stenting was statistically superior to bypass surgery after 1 year of follow-up, said Dr. Serruys.

After adjustment for baseline differences in the patients enrolled in both studies, the combined rate of major adverse events was 8.1% in the patients who underwent stenting and 13.1% among the patients who had bypass surgery.

The superiority of stenting with sirolimus-eluting stents in ARTS II contrasted with the results of the bare-metal-stent arm of ARTS I. In that series of 600 patients, done concurrently with the coronary bypass arm, the combined rate of major adverse events was 26.5% after 1 year, primarily because the rate of clinically necessary revascularization was 17.0%.

The difference in revascularization rates between ARTS I, with bare-metal stents, and ARTS II, with drug-eluting stents, “shows the difference that drug-eluting stents make,” commented Fayez Shamoon, M.D., a cardiologist at St. Michael's Medical Center in Newark, N.J. Based on the new results, “most interventional cardiologists would be willing to treat triple-vessel disease with a drug-eluting stent,” except in patients with diabetes, left main disease, or a left ventricular ejection fraction of 35% or less, he told this newspaper.

ORLANDO, FLA. — Stenting may have finally edged past coronary bypass surgery for treating multivessel coronary disease, according to the results from an uncontrolled series of 607 patients who underwent revascularization using drug-eluting stents.

One year after patients underwent multivessel revascularization with sirolimus-eluting (Cypher) coronary stents, their rate of major adverse events was better than the rate in a similar series of patients who underwent coronary bypass graft (CABG) surgery in the late 1990s, Patrick Serruys, M.D., said at the annual meeting of the American College of Cardiology.

“This study is a breakthrough,” commented Valentin Fuster, M.D., director of the cardiovascular institute at Mount Sinai Medical Center in New York. “Even though this was not a prospective, randomized, controlled study, I'm convinced that for patients with multivessel disease, drug-eluting stents may have more of an impact today on the rate of death and myocardial infarction than coronary artery bypass grafting.”

The biggest question remaining is whether surgery or drug-eluting-stent placement is the best treatment for such patients with diabetes. In the new study, 26% of enrolled patients had diabetes, so the applicability of the results to patients with diabetes remains unclear.

In this multicenter series, 54% of patients had triple-vessel disease, and 46% had two-vessel disease. All patients were treated with percutaneous coronary intervention using sirolimus-eluting coronary stents. The Arterial Revascularization Therapies Study Part II (ARTS II) was designed to test whether multivessel stenting was not inferior to CABG.

The study's primary end point was the combined rate of death, MI, stroke or transient ischemic attack, and need for revascularization 1 year after treatment. This combined rate was 10.4%, reported Dr. Serruys, chief of interventional cardiology at the thorax center of Erasmus University in Rotterdam, the Netherlands.

This rate was compared with the 11.7% rate in a very similar series of 605 patients who underwent CABG during the late 1990s in ARTS I, said Dr. Serruys.

In ARTS II, the incidence of death was 1.0%, the rate of cerebrovascular events was 0.8%, the rate of MI was 1.2%, and the rate of clinically necessary revascularization procedures was 7.4%. (See box.)

In the historic series of CABG patients, the 1-year rate of death was 2.7%, the rate of cerebrovascular events was 1.8%, the rate of MI was 3.5%, and the rate of clinically necessary revascularization was 3.7%.

Comparison of the combined adverse events showed that stenting was not inferior to CABG. The results further showed that stenting was statistically superior to bypass surgery after 1 year of follow-up, said Dr. Serruys.

After adjustment for baseline differences in the patients enrolled in both studies, the combined rate of major adverse events was 8.1% in the patients who underwent stenting and 13.1% among the patients who had bypass surgery.

The superiority of stenting with sirolimus-eluting stents in ARTS II contrasted with the results of the bare-metal-stent arm of ARTS I. In that series of 600 patients, done concurrently with the coronary bypass arm, the combined rate of major adverse events was 26.5% after 1 year, primarily because the rate of clinically necessary revascularization was 17.0%.

The difference in revascularization rates between ARTS I, with bare-metal stents, and ARTS II, with drug-eluting stents, “shows the difference that drug-eluting stents make,” commented Fayez Shamoon, M.D., a cardiologist at St. Michael's Medical Center in Newark, N.J. Based on the new results, “most interventional cardiologists would be willing to treat triple-vessel disease with a drug-eluting stent,” except in patients with diabetes, left main disease, or a left ventricular ejection fraction of 35% or less, he told this newspaper.